Inventor · disambiguated record
James Butler
Also filed as: BUTLER JAMES · BUTLER JAMES E · BUTLER JAMES FRANCIS
23 granted patents·17 pending applications·340 citations·filing 1974–2024
96Inventor score
Top patents by PatentIndex Score
40 records- 0198US9249415B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Feb 2, 2016·24 cites·30 claims
- 0297US11034958B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·7 cites·17 claims
- 0396US11873491B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 16, 2024·2 cites·32 claims
- 0496US10988768B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Apr 27, 2021·3 cites·21 claims
- 0596US9850488B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Dec 26, 2017·11 cites·62 claims
- 0696US9701963B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Jul 11, 2017·9 cites·32 claims
- 0796US4062750AThin film electrochemical electrode and cellBUTLER JAMES FRANCIS·Filed 1974·Granted Dec 13, 1977·201 cites·12 claims
- 0895US10570393B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Feb 25, 2020·17 cites·46 claims
- 0995US9783806B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Oct 10, 2017·16 cites·30 claims
- 1094US10934544B2Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·15 cites·23 claims
- 1194US10913950B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Feb 9, 2021·5 cites·20 claims
- 1291US10829763B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 10, 2020·4 cites·17 claims
- 1390US11198872B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Dec 14, 2021·6 cites·33 claims
- 1490US11162098B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 2, 2021·2 cites·19 claims
- 1589US11408001B1Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 9, 2022·1 cites·29 claims
- 1689US11142766B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 12, 2021·4 cites·21 claims
- 1789US10407679B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·5 cites·43 claims
- 1888US10246713B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·6 cites·14 claims
- 1988US2024309387A1TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2088US2025051765A1APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2187US12492401B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Dec 9, 2025·0 cites·23 claims
- 2286US11725209B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 15, 2023·1 cites·20 claims
- 2384US12338439B2Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Jun 24, 2025·0 cites·16 claims
- 2482US2023068339A1APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2580US2024294911A1INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2678US10494632B2Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Dec 3, 2019·1 cites·22 claims
- 2778US2024254482A1METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)ALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2876US2021254076A1TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2974US11066670B2Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Jul 20, 2021·0 cites·17 claims
- 3073US2022042012A1INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3173US2022119815A1Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3272US2021246447A1Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3370US2020080088A1APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3469US2022267767A1METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)ALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3568US2017268005A1COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3666US2018100150A1Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3763US2018087058A1TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3860US2020208150A1METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)ALNYLAM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3941US2003170906A1Conductive diamond spectrographic cells and method of useUNIV MICHIGAN STATE·Filed 2003·Application pending·0 cites
- 4039US2012245076A1Compositions and methods for delivering rnai using apoeNAKAYAMA TOMOKO·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when James Butler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →